Traphaco: 53 years dedicated to the health of Vietnam.

In November 2025, Traphaco celebrated its 53rd anniversary with the message '53 years for the health of Vietnam', affirming its journey of more than half a century dedicated to community health through quality, science, and continuous innovation.

A pioneering enterprise in modernizing traditional Eastern medicine.

From a small production unit within the railway industry established in 1972, Traphaco was founded with the mission of producing medicines to serve the North-South railway line throughout the war years.

During the period of reform, with its strategic vision and pioneering spirit, Traphaco was a leading enterprise in modernizing Vietnamese traditional medicine, opening up a different path - combining traditional medical knowledge with modern technology.

Since 2009, Traphaco has implemented the GreenPlan Project - Research and sustainable development of Vietnamese medicinal resources, forming a "four-party" model (State - Scientists - Farmers - Businesses), closely linking production and community livelihoods.

To date, the company has developed 11 GACP-WHO certified medicinal plant growing areas in Lao Cai, Ninh Binh (formerly Nam Dinh), Phu Tho, Dak Lak (formerly Phu Yen), etc., with more than 880 households participating in planting and harvesting medicinal plants according to standards, and thousands of hectares of medicinal plants controlled according to GACP-WHO guidelines.

Representatives of Traphaco's leadership team receive the Vietnam record certificate.

Traphaco is one of the first enterprises in Vietnam to build a large-scale GACP-WHO certified cultivation area chain, becoming a model for the Vietnamese pharmaceutical industry in terms of quality from source and transparency throughout the entire process.

According to the GACP-WHO standard of the World Health Organization, every process from seed selection, cultivation, irrigation, harvesting, storage to transportation of medicinal herbs is strictly controlled to ensure a safe, clean, chemical-free input of medicinal herbs with the highest possible active ingredient content.

Each growing region not only provides high-quality raw materials but also serves as a sustainable poverty alleviation model, helping people earn a stable income many times higher than rice and corn farming, contributing to land and forest conservation and the preservation of the native ecosystem.

Entering the integration phase, Traphaco has defined a parallel development strategy: high-end traditional medicine and high-quality modern medicine. Familiar brands such as Boganic, Hoat Huyet Duong Nao, Tottri, and Cebraton continue to affirm their top market positions, while Boganic Premium and Cebraton Premium open a new chapter for modern traditional medicine products.

Traphaco is confident in the strong competitiveness of its two strategic product lines.

High-quality medicine at a reasonable price.

In the pharmaceutical sector, Traphaco has implemented a strategic cooperation with Daewoong Group, one of the top three pharmaceutical companies in South Korea, to receive technology transfer and enhance its capacity to produce high-quality medicines. From 2021 to the present, the project has entered phase 3 with approximately 40 products transferred from Daewoong Group, out of a total of 8 phases and 70 key products of the program.

Traphaco is implementing a strategic cooperation with Daewoong Group in the transfer of technology for the production of high-quality pharmaceuticals.

Simultaneously, Traphaco is proactively promoting research and development of bioequivalent (BE) and first-generic drugs to meet the growing treatment needs of Vietnamese patients. This collaboration not only shortens the research and development process but also enhances technical capabilities, opening up opportunities for exporting "Made in Vietnam" drugs.

Bioequivalent drugs (BE) are Traphaco's flagship product in the high-quality pharmaceutical sector.

In 2025, Traphaco will implement a dual strategy: restructuring its distribution system and undergoing a comprehensive digital transformation. The company has streamlined its branch model, established a nationwide order center and a specialized logistics company, and integrated artificial intelligence (AI) into its core operations: pharmaceutical testing, accounting, supply chain, customer service, and marketing.

The AI-powered raw material quality management system allows for the traceability of each batch of medicinal herbs from the growing region to the finished product, enhancing control capabilities and operational efficiency.

Throughout its development and brand building journey, the company has consistently maintained its "National Brand" title, been honored in the Top 10 Sustainable Businesses (CSI), Top 50 Best Listed Companies in Vietnam (Forbes), Outstanding and Sustainable Asian Businesses, and Top 10 Golden Stars of Vietnam for many years. Its flagship products such as Boganic, Hoat Huyet Duong Nao, Tottri, and Cebraton consistently hold top market share positions in the Vietnamese traditional medicine market.

With over half a century of accumulated experience, Traphaco has defined its strategy for the next phase as a "technology-based pharmaceutical enterprise" model, built on three pillars: R&D, technology transfer, and a digitized supply chain. The company is currently implementing a project to build a manufacturing plant that meets EU-GMP standards, expanding research and application of AI in pharmaceutical testing and quality management, aiming for international standards in production, safety, and sustainability.

"Traphaco 53 years for Vietnamese health" is not only a tribute but also a commitment to the millions of consumers who have trusted and supported Traphaco.

In the first nine months of 2025, Traphaco's revenue increased by 8.5%, and profit increased by 8% compared to the same period in 2024. The two strategic product groups: high-end traditional medicine and high-quality modern medicine, grew by 65% ​​and 55% respectively, contributing 13% of total revenue and becoming the company's key drivers.

Traphaco aims to have 17 bioequivalent pharmaceutical products by the end of 2025, helping Vietnamese patients access high-quality medicines at reasonable costs.

Source: https://thanhnien.vn/traphaco-53-nam-vi-suc-khoe-viet-185251127164511917.htm